Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of nitric oxide and NCX4040 on the reversal of drug resistance in human tumor cells

ABSTRACT: Ovarian tumor cells (OVCA-8 and its reistant variant) were treated with NCX4040 for different times in 10% FBS and RNA was isolated by triazol method

ORGANISM(S): Homo sapiens

PROVIDER: GSE212017 | GEO | 2023/01/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.

Project description: Not available

| S-EPMC6892394 | biostudies-literature

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

Project description:Identification of ovarian cancer (OvCa) patient subpopulations with increased sensitivity to targeted therapies could offer significant clinical benefit. We report that 22 % of the high grade OvCa tumors at diagnosis express CIP2A oncoprotein at low levels. Further, regardless of their significantly lower likelihood of disease relapse after standard chemotherapy, a portion of relapsed tumors retain their CIP2A-deficient phenotype. Through a screen for therapeutics that would preferentially kill CIP2A-deficient OvCa cells, we identified reactive oxygen species inducer APR-246, tested previously in OvCa clinical trials. Consistent with CIP2A-deficient OvCa subtype in humans, CIP2A is dispensable for development of MISIIR-Tag-driven mouse OvCa tumors. Nevertheless, CIP2A null OvCa tumor cells from MISIIR-Tag mice displayed APR-246 hypersensitivity both in vitro and in vivo. Mechanistically, the lack of CIP2A expression hypersensitizes the OvCa cells to APR-246 by inhibition of NF-kB activity. Accordingly, combination of APR-246 and NF-kB inhibitor compounds strongly synergized in killing of CIP2A positive OvCa cells. Collectively, the results warrant consideration of clinical testing of APR-246 for CIP2A-deficient OvCa tumor subtype patients. Results also reveal CIP2A as a candidate APR-246 combination therapy target for ovarian cancer.

2022-02-02 | GSE195984 | GEO

Cancer-Associated Mesothelial Cell-Derived ANGPTL4 and STC1 Promote the early steps of Ovarian Cancer metastasis

Project description:Ovarian Cancer preferentially metastasizes in association with mesothelial cell-lined surfaces.We sought to determine if mesothelial cells are required for OvCa metastasis and detect alterations in mesothelial cell gene expression upon interaction with OvCa cells. To evaluate the OvCa-induced transcriptome changes in mesothelial cells, primary human mesothelial cells from 10 patients were treated with OvCa conditioned media or ascites and RNAseq analysis was performed.

2023-01-25 | GSE223165 | GEO

Derived Small Extracellular Vesicles

Project description:Epithelial ovarian cancer (OvCa) remains a leading cause of mortality among gynecological cancers. The median age of diagnosis is 63 and there exists a strong correlation between advanced age, OvCa incidence and disease stage. sEVs were analyzed using to LC-MS/MS analysis to identify and quantify sEV thier protein cargoes and were incubated with OvCa cells to evaluate their effect on pro-metastatic behaviors.

2025-07-14 | PXD061884 | Pride

Nitric Oxide–Dependent Stabilization of Vimentin Confers Chemoresistance in Ovarian Cancer

Project description:High-grade serous ovarian carcinoma (HGSC) is often diagnosed at an advanced stage and is characterized by an immunosuppressive tumor microenvironment that facilitates disease progression, therapeutic resistance, and poor survival. We recently demonstrated that nitric oxide (NO) blockade enhances the response of metaplastic breast cancer to PI3K inhibition and taxane therapy by reducing S-nitrosylation-mediated activation of the JNK/c-Jun pathway, thereby promoting tumor differentiation, suppressing stemness, and improving survival in patient-derived xenograft models. Here, we demonstrate that inducible nitric oxide synthase (iNOS) is constitutively expressed in high-grade serous ovarian carcinoma and that pharmacologic inhibition of NO signaling with the pan-NOS inhibitor NG-monomethyl-L-arginine (L-NMMA) enhances Cisplatin efficacy by reprogramming the tumor microenvironment. By targeting NO signaling with either L-NMMA or through CRISPR/CAS9-mediated iNOS knockout and iNOS small interfering RNA (siRNA), we impaired epithelial-mesenchymal transition (EMT) by inhibiting NO stabilizing effects on Vimentin, both in vitro and in vivo models. Mechanistically, L-NMMA-mediated inhibition of iNOS signaling reduced S-nitrosylation, accelerated Vimentin ubiquitination, and promoted its proteasome-dependent degradation. These findings identify iNOS-mediated S-nitrosylation as a key regulator of Vimentin stability and EMT and suggest that therapeutic inhibition of NO signaling may increase Cisplatin sensitivity in high-grade serous ovarian carcinoma and improve patient outcomes.

2026-05-15 | GSE318175 | GEO

NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells.

Project description: Not available

| S-EPMC8038154 | biostudies-literature

Role of nitric oxide and nitric oxide synthase isoforms in pulmonary emphysema.

Project description:The purpose of this study is to comprehensively elucidate the role of nitric oxide and nitric oxide synthase isoforms in pulmonary emphysema using cap analysis of gene expression (CAGE) sequencing.

2021-01-18 | GSE164521 | GEO

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

Project description:Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient population, more TCRs targeting peptides derived from different TAAs binding in various HLA class I molecules are essential. By performing a differential gene expression analysis using mRNA-seq datasets, PRAME, CTCFL and CLDN6 were selected as strictly tumor-specific TAAs, with high expression in ovarian cancer and at least 20-fold lower expression in all healthy tissues of risk. In primary OVCA patient samples and cell lines we confirmed expression and identified naturally expressed TAA-derived peptides in the HLA class I ligandome. Subsequently, high-avidity T-cell clones recognizing these peptides were isolated from the allo-HLA T-cell repertoire of healthy individuals. Three PRAME TCRs and one CTCFL TCR of the most promising T-cell clones were sequenced, and transferred to CD8+ T cells. The PRAME TCR-T cells demonstrated potent and specific antitumor reactivity in vitro and in vivo. The CTCFL TCR-T cells efficiently recognized primary patient-derived OVCA cells, and OVCA cell lines treated with demethylating agent 5-aza-2′-deoxycytidine (DAC). The identified PRAME and CTCFL TCRs are promising candidates for the treatment of patients with ovarian cancer, and are an essential addition to the currently used HLA-A*02:01 restricted PRAME TCRs. Our selection of differentially expressed genes, naturally expressed TAA peptides and potent TCRs can improve and broaden the use of T-cell therapies for patients with ovarian cancer or other PRAME or CTCFL expressing cancers.

2023-03-10 | PXD040651 | Pride

Effect of nitric oxide on the reversal of adriamycin resistance in NCI/ADR-RES tumor cells

Project description:To understand how nitric oxide is involved in reversal of resistance and investigate mechanisms of Pgp-dependent efflux and genes in involved in drug resistance.

2020-08-22 | GSE136201 | GEO

Nitric Oxide-Driven Nanomotor for Deep Tissue Penetration and Multidrug Resistance Reversal in Cancer Therapy.

Project description: Not available

| S-EPMC7856908 | biostudies-literature